Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs CLAG-M in Medically Less-Fit Adults With AML or Other High-Grade Myeloid Neoplasm
NCT04195945Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2020
- Primary completion
- Jun 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML) and myeloid neoplasm (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Overall Survival at 3 months. Started May 2020; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myeloid neoplasm
Beyond the preview
Go deeper on NCT04195945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195945.